Depression Clinical Trials in Tucson

View 9 new treatments for depression near you in Tucson, AZ near me. Every day, Power helps over 527 depression patients connect with leading medical research.
View 10 trials in Tucson
Filter (10)

ALTO-300 for Depression

Alto Neuroscience Clinic, Tucson + 1 more

This trial is testing ALTO-300, a new medication, to see if it can make antidepressants work better for patients who are already taking them.

Verified

Recruiting
Phase 2
Est. 3 - 6 Weeks
Adam Savitz, MD, PhD
Study Director

ECT vs. Ketamine for Depression

Research Clinic, Tucson + 1 more

This trial compares two treatments for patients with severe depression who are at risk of suicide. One treatment uses electric currents to change brain activity, while the other uses a low dose of a fast-acting drug. The goal is to find out which treatment works better for rapid relief. The drug has recently emerged as a fast-acting alternative for patients with treatment-resistant depression.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 4 - 6 Weeks
Amit Anand, MD
Principal Investigator

REL-1017 for Depression

Relmada Clinic, Tucson + 1 more

This trial tests if adding REL-1017 to current antidepressant treatments can better help people with Major Depressive Disorder. Participants will take their usual antidepressants plus either REL-1017 or another substance. The goal is to see if REL-1017 can improve their depression symptoms. REL-1017 (esmethadone) has shown potential rapid and sustained antidepressant effects in previous trials.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Paul Greene, PhD
Study Director

Aticaprant for Major Depressive Disorder

Janssen Clinic, Tucson + 3 more

This trial is testing aticaprant to see if it can help people with major depressive disorder who still feel very down and don't enjoy things despite taking other antidepressants. The study focuses on adults who haven't responded well to their current treatments. Aticaprant works by blocking a specific brain receptor, which might help improve their mood and reduce depressive symptoms.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director

Psilocybin for Treatment-Resistant Depression

COMPASS Pathways Clinic, Tucson + 1 more

This trial is testing a new medication called COMP360 to help people with severe depression that hasn't improved with other treatments. The study involves adults aged 18 and older. Researchers want to see if a single dose of COMP360 can reduce depression symptoms when given with psychological support.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Aticaprant for Depression

Janssen Clinic, Tucson + 1 more

This trial is testing if aticaprant can help adults with major depressive disorder who haven't responded well to current antidepressants. The medication works by targeting brain chemicals to improve mood and pleasure.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director

Aticaprant for Depression

Janssen Clinic, Tucson + 3 more

This trial is testing if adding aticaprant to current antidepressants is safe and well-tolerated in people with major depressive disorder. The goal is to see if it can help improve their treatment.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 4 - 6 Weeks
Janssen Research & Development, LLC Clinical trial
Study Director

BI 1569912 for Depression

Boehringer Ingelheim Clinic, Tucson + 1 more

This trial tests a new medicine, BI 1569912, for adults with depression who haven't improved with other treatments. Participants take the medicine daily while continuing their usual therapy. The study checks if the new medicine helps reduce depression symptoms.Show More
Recruiting
Phase 2
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team

ALTO-203 for Depression

Alto Neuroscience Clinic, Tucson + 1 more

The goal of this clinical trial is to determine the pharmacodynamic effects of ALTO-203 in patients with MDD in a randomized, placebo-controlled, single-dose crossover treatment period. Additionally, safety, tolerability, and PK will be assessed in a subsequent randomized placebo-controlled multi-dose parallel-group treatment period of 28 days. Participants will complete subjective response questionnaires and perform cognitive tasks during the single-dose period, in which participants will receive ALTO-203 25 μg and 75 μg, as well as placebo. During the multiple-dose period, participants will receive either ALTO-203 25 μg, 75 μg , or placebo. Safety will be assessed over the single dose and 28-day multiple dose periods.Show More
Recruiting
Phase 2
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team

Altering Default Mode Network Activity With Transcranial Focused Ultrasound to Reduce Depressive Symptoms

Research Clinic, Tucson + 1 more

Depression is a leading cause of disability worldwide, affecting roughly 21 million adults. Repetitive Negative Thought (RNT) has been identified as a potential maintaining factor in depression, such that those who exhibit higher degrees of RNT endorse greater symptoms. Research also suggests that the Default Mode Network (DMN), responsible for self-referential processing, plays an important role in depression wherein it has been linked to RNT. In depressed individuals, this network appears to be hyper-connected, or "too connected", within itself which, in turn, is thought to promote RNT. Half of depressed individuals are treatment-resistant, creating a critical need to identify more effective interventions derived from a better mechanistic understanding of the development and maintenance of depression. Non-invasive Transcranial-Focused Ultrasound Stimulation (tFUS) is promising for the treatment of depression. tFUS directs a low-intensity (nonthermal) focused ultrasound beam that passes safely through the skull. Compared to other noninvasive neuromodulation approaches, tFUS can target deeper brain regions with high spatial precision. The present study is an exploratory non-blinded single treatment study to investigate whether tFUS targeting a major hub of the DMN, the anterior-medial prefrontal cortex, can improve depression symptoms and reduce RNT. Twenty depressed individuals with high RNT (75th percentile) will complete up to eleven ultrasound sessions targeting the anterior medial prefrontal cortex, a hub of the brain's default mode network that has been found to be hyper-connected in depression. MRI scans will be obtained before the first and after the last ultrasound sessions. Based on previous literature, it is predicted that depression interview ratings and self-report symptoms will decrease after the intervention, and also that DMN connectivity will decrease following intervention.Show More
Waitlist

No Placebo Trial

Phase 1 & 2
Est. 4 - 6 Weeks
Jessica N Schachtner, BA
Principal Investigator
Page 1 of 1

Frequently Asked Questions

How much do depression clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do depression clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across depression trials in Tucson, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for depression patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Why are others applying to these studies?

  • I have tried two other drugs that didn't have any positive affect on my mental health and am hoping that trying out this trial will help me find a solution.

    M.A. Patient

    Depression Patient

  • I've tried many anti-depressants in my 45 year struggle with Major Depression. I'm hoping this study is the 'game changer'

    B.E. Patient

    Late-Life Depression Patient

  • I've tried more then 5 drugs for depression and it's very depressing frustrating when they do not work, or even help nothing, I'm still looking for that one or 2 that will help

    A.L. Patient

    Major Depression Patient